Hepatitis B Delta: assessment of the knowledge and practices of hepato-gastroenterologists practicing in non-academic settings in France.

Humans France Middle Aged Female Male Antiviral Agents / therapeutic use Practice Patterns, Physicians' / statistics & numerical data Gastroenterology Gastroenterologists Liver Cirrhosis / virology Adult Health Knowledge, Attitudes, Practice Hepatitis Delta Virus / isolation & purification Biopsy Hepatitis B Surface Antigens / blood

Journal

European journal of gastroenterology & hepatology

ISSN: 1473-5687

Titre abrégé: Eur J Gastroenterol Hepatol

Pays: England

ID NLM: 9000874

Informations de publication

Date de publication:
01 Jun 2024

Historique:

medline: 29 4 2024

pubmed: 29 4 2024

entrez: 29 4 2024

Statut: ppublish

Résumé

Data on the management of Hepatitis B-Delta (HB-D) by hepatogastroenterologists (HGs) practicing in nonacademic hospitals or private practices are unknown in France. We aimed to evaluate the knowledge and practices of HGs practicing in nonacademic settings regarding HB-D. A Google form document was sent to those HGs from May to September 2021. A total of 130 HGs (mean age, 45 years) have participated in this survey. Among HBsAg-positive patients, Delta infection was sought in only 89% of cases. Liver fibrosis was assessed using FibroScan in 77% of the cases and by liver biopsy in 81% of the cases. A treatment was proposed for patients with >F2 liver fibrosis in 49% of the cases regardless of transaminase levels and for all the patients by 39% of HGs. Responding HGs proposed a treatment using pegylated interferon in 50% of cases, bulevirtide in 45% of cases and a combination of pegylated interferon and bulevirtide in 40.5% of cases. Among the criteria to evaluate the treatment efficacy, a decrease or a normalization of transaminases was retained by 89% of responding HGs, a reduction of liver fibrosis score for 70% of them, an undetectable delta RNA and HBsAg for 55% of them and a 2 log 10 decline in delta viremia for 62% of the cases. Hepatitis Delta screening was not systematically performed in HBsAg-positive patients despite the probable awareness and knowledge of the few responders who were able to prescribe treatments of hepatitis delta.

Sections du résumé

BACKGROUND BACKGROUND

Data on the management of Hepatitis B-Delta (HB-D) by hepatogastroenterologists (HGs) practicing in nonacademic hospitals or private practices are unknown in France.

OBJECTIVE OBJECTIVE

We aimed to evaluate the knowledge and practices of HGs practicing in nonacademic settings regarding HB-D.

METHODS METHODS

A Google form document was sent to those HGs from May to September 2021.

RESULTS RESULTS

A total of 130 HGs (mean age, 45 years) have participated in this survey. Among HBsAg-positive patients, Delta infection was sought in only 89% of cases. Liver fibrosis was assessed using FibroScan in 77% of the cases and by liver biopsy in 81% of the cases. A treatment was proposed for patients with >F2 liver fibrosis in 49% of the cases regardless of transaminase levels and for all the patients by 39% of HGs. Responding HGs proposed a treatment using pegylated interferon in 50% of cases, bulevirtide in 45% of cases and a combination of pegylated interferon and bulevirtide in 40.5% of cases. Among the criteria to evaluate the treatment efficacy, a decrease or a normalization of transaminases was retained by 89% of responding HGs, a reduction of liver fibrosis score for 70% of them, an undetectable delta RNA and HBsAg for 55% of them and a 2 log 10 decline in delta viremia for 62% of the cases.

CONCLUSION CONCLUSIONS

Hepatitis Delta screening was not systematically performed in HBsAg-positive patients despite the probable awareness and knowledge of the few responders who were able to prescribe treatments of hepatitis delta.

Identifiants

DOI: 10.1097/MEG.0000000000002707 PMID: 38683191

pubmed: 38683191

doi: 10.1097/MEG.0000000000002707

pii: 00042737-202406000-00007

doi:

Substances chimiques

Antiviral Agents 0

Hepatitis B Surface Antigens 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

Pagination

735-741

Informations de copyright

Références

Asselah T, Rizzetto M. Hepatitis D virus infection. N Engl J Med 2023; 389:58–70.

Villeret F, Loustaud-Ratti V, Zoulim F. Virologie, dépistage et diagnostic de l’hépatite Delta. Hépato-Gastro et Oncologie Digestive 2022; 29:15–22.

Roulot D, Brichler S, Layese R, Ben Abdesselam Z, Zoulim F, Thibault V, et al. Origin, HDV genotype and persistent viremia determine outcome and treatment response in patients with chronic hepatitis delta. J Hepatol 2020; 73:1046–1062.

R Core Team (2019). R: a language and environment for statistical computing. R. Foundation for Statistical Computing, Vienna, Austria. HYPERLINK ‘https://www.R-project.org/’.

Stockdale AJ, Kreuels B, Henrion MYR, Giorgi E, Kyomuhangi I, de Martel C, et al. The global prevalence of hepatitis D virus infection: systematic review and meta-analysis. J Hepatol 2020; 73:523–532.

Gordien E. L’infection par le virus de l’hépatite Delta Données françaises récentes. Bulletin Epidémiologique Hebdomadaire 2015; 19-20:347–352.

Servant-Delmas A, Le Gal F, Gallian P, Gordien E, Laperche S. Increasing prevalence of HDV/HBV infection over 15 years in France. J Clin Virol 2014; 59:126–128.

Piroth L, Pol S, Lacombe K, Miailhes P, Rami A, Rey D, et al.; GERMIVIC Study Group. Management and treatment of chronic hepatitis B virus infection in HIV positive and negative patients: the EPIB 2008 study. J Hepatol 2010; 53:1006–1012.

Saboni L, Brouard C, Gautier A, et al. Prévalence des hépatites chroniques C et B, et antécédents de dépistage en population générale en 2016: contribution à une nouvelle stratégie de dépistage, Baromètre de Santé publique France-BaroTest. Bull Epidemiol Hebd 2019:24–25: 469-77.

ANRS, AFEF. Dépistage des personnes infectées par les virus des hépatites B ou C. Rapport de recommandations sur la prise en charge des personnes infectées par les virus de l’hépatite B ou de l’hépatite C. Sous la direction du Pr Daniel Dhumeaux et sous l’égide de l’ANRS et de l’AFEF, 2014. HYPERLINK ‘https://solidarites-sante.gouv.fr/IMG/pdf/Rapport_Prise_en_charge_Hepatites_2014.pdf’.

Gish RG, Yi DH, Kane S, Clark M, Mangahas M, Baqai S, et al. Coinfection with hepatitis B and D: epidemiology, prevalence and disease in patients in Northern California. J Gastroenterol Hepatol 2013; 28:1521–5. 9.

Wranke A, Pinheiro Borzacov LM, Parana R, Lobato C, Hamid S, Ceausu E, et al.; Hepatitis Delta International Network. Clinical and virological heterogeneity of hepatitis delta in different regions world-wide: The Hepatitis Delta International Network (HDIN). Liver Int 2018; 38:842–850.

Trimoulet P, Foucher J, Tumiotto C, et al. On the way to HDV elimination. A call for reflex testing in the large program ‘Bordeaux Metropolis without viral hepatitis’ Abs 720. Hepatology 2021; 74(S1):439A–440A.

Palom AR-SA, Vico J, Pacín B, Vargas E, Barreira-Díaz A, et al. Implementation of anti-HDV reflex testing among HBsAg-positive individuals increases testing for hepatitis D. JHEP Rep 2022; 4:1–4.

Crespo J, Cabezas J, Aguilera A, Berenguer M, Buti M, Forns X, et al. Recommendations for the integral diagnosis of chronic viral hepatitis in a single analytical extraction. Gastroenterol Hepatol 2022; 46:150–162.

Ministry of Health Brazil. Clinical Protocol and therapeutic guidelines for hepatitis B and coinfections. Ministério da Saúde; 2017.

Brichler SRD, Roulot D, Dziri S, Gerber A, Le Gal F, Delagreverie H, et al. Hepatitis delta virus reflex testing in patients with hepatitis B improves the HDV screening cascade: 10 years of real-word experience from Avicenne University Hospital, France. J Hepatol 2022; 77:S271.

Center for Disease Analysis Foundation. HBV Cascade of Care 2022 HYPERLINK ‘https://cdafound.org/polaris-observ-access/’.

Homie AR, Maria B, Norah AT, Stefan Z, Cihan Y, Junko T, et al. Hepatitis D double reflex testing of all hepatitis B carriers in low-HBV- and high-HBV/HDV-prevalence countries. J Hepatol 2023; 79:576–580.

Lampertico P, Agarwal K, Berg T, Buti M, Janssen HLA, Papatheodoridis G, et al. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol 2017; 67:370–398.

Haute Autorité de Santé (HAS). Hépatite B Chronique. HAS, 2006. Guide- Affection de Longue durée. https://www.has-sante.fr/jcms/c_554191/fr/ald-n-6-actes-et-prestations-sur-l-hepatite-chronique-b-actualisation-mai-2016.

Leroy V, Chevaliez S, Decraecker M, Roulot D, Nana J, Asselah T, et al. Non-invasive diagnosis and follow-up of chronic infection with Hepatitis B virus. Clin Res Hepatol Gastroenterol 2021; 46:101773.

Da BL, Surana P, Kleiner DE, Heller T, Koh C. The Delta-4 fibrosis score (D4FS): a novel fibrosis score in chronic hepatitis D. Antiviral Res 2020; 174:104691.

Baron A, Asselah T. Hépatite delta: du diagnostic à la prise en charge. Hépato-Gastro et Oncologie Digestive 2022; 29:23–33.

Lutterkort GL, Wranke A, Yurdaydin C, Budde E, Westphal M, Lichtinghagen R, et al. Non-invasive fibrosis score for hepatitis delta. Liver Int 2017; 37:196–204.

Roulot D, Hanslik B. Épidémiologie et histoire naturelle de l’hépatite Delta. Hépato-Gastro et Oncologie Digestive 2022; 29:7–14.

Fattovich G, Giustina G, Christensen E, Pantalena M, Zagni I, Realdi G, et al. Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. Gut 2000; 46:420–426.

Roulot D, Nahon P, Layese R, et al. PP_05 L’incidence du carcinome hépatocellulaire est plus élevée au cours des cirrhoses co-infectées VHB-VHD qu’au cours des cirrhoses mono-infectées VHB. Congrès AFEF 2021. [cité 30 janv 2022]. Disponible à l’adresse suivante: https://www.jle.com/fr/revues/hpg/e-docs/hepatite_delta_du_diagnostic_a_la_prise_en_charge322731/article.phtml?tab=references.

Alfaiate D, Clément S, Gomes D, Goossens N, Negro F. Chronic hepatitis D and hepatocellular carcinoma: a systematic review and meta-analysis of observational studies. J Hepatol 2020; 73:533–539.

Etzion O, Hamid S, Lurie Y, et al. PS-052-Résultats de fin d’étude de l’étude LIMT HDV: 36 % de réponse virologique durable à 24 semaines après le traitement par peginterféron lambda en monothérapie chez des patients atteints d’une infection chronique par le virus de l’hépatite delta. J Hépatol 2019; 70:e32.